Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology

  • Enochian BioSciences Inc ENOB has acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza. 
  • The technology is delivered by a nanoparticle, allowing it to either rapidly treat an infection or to wait in ambush for a cell to become infected to prevent (prophylaxis) future infections. 
  • Since the target cells of the viruses live up to 20 months in human airways, it is possible that a single inhalation could both rapidly treat and protect against infection for relatively long periods.
  • Recently, the FDA accepted Enochian's pre-IND request for a potential functional cure or treatment of HIV. 
  • The request was based on the results of a 54-year man living with HIV who had failed to suppress the virus with antiviral therapy.
  • Last week, the company also announced a $29 million direct offering.
  • Price Action: ENOB shares are up 13.8% at $6.60 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!